| Background: Although ultrasound- or computed tomography-guided percutaneous biopsy is the gold standard for liver disease, endoscopic ultrasound-guided tissue acquisition (EUS-TA) is gaining attention as an alternative. Purpose: To investigate the usefulness of EUS-TA for liver diseases. Methods: Single center, retrospective study. The subjects were cases in which EUS-TA for liver disease was attempted between 2016 and 2023. Results: 127 patients were included. The indications involved 121 cases of focal liver lesions, 6 cases of diffuse liver disease. For focal liver lesions, the median size was 29 mm, and the lesion was located in the left lobe in 83 cases (68%), the right lobe in 31 cases (25%), and the caudate lobe in 7 cases (6%). Technical success was obtained in 96% (122/127). The needle used were 22G in 61 cases (50%), 25G in 52 cases (42%), and 19G in 9 cases (7%). EUS-TA for focal liver lesions had a sensitivity of 97%, specificity of 100%, and accuracy of 97% and histological diagnosis was possible in all six cases of diffuse liver disease. Adverse events were observed in 2% (abdominal pain in 2 cases, bleeding in 1 case). Conclusion: EUS-TA for liver disease has a feasible outcome, which comparable to percutaneous biopsy. EUS-TA for liver disease is considered not only an alternative in cases where percutaneous procedures are difficult, but also a procedure that could become the first choice. |
